Bonus BioGroup Ltd. (BBIXF)

Bonus BioGroup Income Statement

Financials in millions ILS. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Selling, General & Admin	10.23	11.18	15.74	43.94	8.09
Research & Development	17.61	18.61	21.31	20.79	11.36
Operating Expenses	27.84	29.79	37.05	64.74	19.44
Operating Income	-27.84	-29.79	-37.05	-64.74	-19.44
Interest Expense	-0.78	-0.85	-0.89	-0.57	-0.41
Interest & Investment Income	0.83	2.14	7.28	0.16	-
Currency Exchange Gain (Loss)	-	-	-	-3.93	0.05
Other Non Operating Income (Expenses)	-0.04	-0.03	-8.04	-21.01	-2.22
EBT Excluding Unusual Items	-27.83	-28.53	-38.7	-90.08	-22.02
Pretax Income	-27.83	-28.53	-38.7	-90.08	-22.02
Net Income	-27.83	-28.53	-38.7	-90.08	-22.02
Net Income to Common	-27.83	-28.53	-38.7	-90.08	-22.02
Shares Outstanding (Basic)	1,168	1,168	1,168	1,154	999
Shares Outstanding (Diluted)	1,168	1,168	1,168	1,154	999
Shares Change (YoY)	-	-	1.20%	15.52%	18.72%
EPS (Basic)	-0.02	-0.02	-0.03	-0.08	-0.02
EPS (Diluted)	-0.02	-0.02	-0.03	-0.08	-0.02
Free Cash Flow	-21.72	-27.22	-35.2	-45.65	-16
Free Cash Flow Per Share	-0.02	-0.02	-0.03	-0.04	-0.02
EBITDA	-26.2	-28.14	-34.38	-63.26	-18.38
D&A For EBITDA	1.63	1.65	2.66	1.48	1.07
EBIT	-27.84	-29.79	-37.05	-64.74	-19.44

Source: S&P Global Market Intelligence. Standard template. Financial Sources.